Software Plays Key Role as Elekta Presents Product Developments at ASTRO Meeting

Regulatory News:

Elekta (STO:EKTAB):

Speaking at Elekta’s Capital Markets Day in San Francisco, during the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Niklas Savander, President and CEO, restated his strategic agenda for the company (http://www.elekta.com/pressreleases/897884/elekta-presents-strategic-agenda-to-outgrow-the-market.html), which includes a strong focus on software.

Savander told the audience: "We are not only leaders in radiation therapy systems; we are also a leader in software solutions for the entire cancer care continuum. Our hardware-agnostic treatment planning system and oncology information system platforms are paving the way for an implementation of Information-guided cancer care™ (http://www.elekta.com/information-guided).”

Niklas Savander reiterated that net sales is expected to finish at the lower range of the 7-9 percent interval and that EBITA is expected to grow by approximately 10 percent, both in local currency for the fiscal year 2014/15.

Todd Powell, Executive Vice President Software, explained Elekta’s software vision: "Quite simply, we believe that better information will transform cancer care. Elekta’s Information-guided cancer care solutions will integrate cancer networks, people and information to enable clinicians to provide optimal care.” He said Elekta is uniquely positioned to lead this field as it has had registry solutions for the past 25 years; it has the largest, aggregated oncology database on the market with more than two million patients.

Maurits Wolleswinkel, Executive Vice President Neuroscience, mentioned that Elekta’s Leksell Gamma Knife® Perfexion™ (http://www.elekta.com/healthcare-professionals/products/elekta-neuroscience/gamma-knife-surgery/gamma-knife-perfexion.html) won the Best in KLAS award for fourth consecutive year (http://www.elekta.com/pressreleases/911615/for-fourth-year-in-a-row-elekta-s-leksell-gamma-knife-perfexion-earns-top-rank-in-2014-s-best-in-klas-for-radiation-therapy.html). He said: "At this year's ASTRO, Elekta is showcasing its next generation intracranial radiosurgery solution as a work in progress that will expand clinical versatility.” Wolleswinkel said that users should expect improved fractionation possibilities and better options for image-guided workflows. He also explained how Leksell Gamma Knife® Perfexion™ and Versa HD™ (http://www.versahd.com/) are uniquely complementary solutions for stereotactic treatments.

Kevin Brown, Global Vice President Scientific Research, re-capped developments of Elekta’s first-generation high-field MRI-guided radiation therapy system. "Installation of the machine at UMCU, Utrecht is progressing well. Research on the system was very well received at the American Association of Physicists in Medicine meeting in July this year with several presentations by consortium members (http://www.elekta.com/pressreleases/908118/the-christie-hospital-joins-elekta-and-philips-research-consortium-to-develop-mri-guided-radiation-therapy-system-for-cancer-treatment.html).” He also explained how bringing MRI directly into the treatment room, can further improve treatment accuracy.

Presentations were also given by Jay Hoey, Executive Vice President North America; John Lapré Executive Vice President Brachytherapy; and Dee Mathieson, Senior Vice President Oncology Business Line Management.

# # #

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 18:00 CET on September 15, 2014.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.

This information was brought to you by Cision http://news.cision.com